intravenous methylprednisolone
Pre-clinicalRecruiting 0 watching 0 views this week💤 Quiet
15
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neuromyelitis Optica Spectrum Disorders
Conditions
Neuromyelitis Optica Spectrum Disorders
Trial Timeline
Apr 25, 2025 → Dec 31, 2026
NCT ID
NCT06763848About intravenous methylprednisolone
intravenous methylprednisolone is a pre-clinical stage product being developed by Brain Biotech for Neuromyelitis Optica Spectrum Disorders. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06763848. Target conditions include Neuromyelitis Optica Spectrum Disorders.
Hype Score Breakdown
Clinical
5
Activity
2
Company
2
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06763848 | Pre-clinical | Recruiting |
Competing Products
8 competing products in Neuromyelitis Optica Spectrum Disorders
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Satralizumab 120 mg | Chugai Pharmaceutical | Approved | 85 |
| Satralizumab + Placebo + Baseline Treatment | Chugai Pharmaceutical | Phase 3 | 77 |
| Satralizumab + Placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| satralizumab + azathioprine (AZA) + mycophenolate mofetil (MMF) + oral corticosteroids | Roche | Phase 3 | 77 |
| Satralizumab | Roche | Phase 3 | 77 |
| UPLIZNA | Amgen | Pre-clinical | 22 |
| Inebilizumab | Amgen | Phase 2 | 51 |
| Inebilizumab | Amgen | Approved | 84 |